Sujata Patil, Ph.D.
Affiliations: | 2004 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
Biostatistics BiologyGoogle:
"Sujata Patil"Parents
Sign in to add mentor| Trivellore E. Raghunathan | grad student | 2004 | University of Michigan | |
| (Jointly modeling latent trajectories and a subsequent outcome variable: A Bayesian approach.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| LeVee A, Spector K, Larkin B, et al. (2023) Incidence and prognostic impact of HER2-positivity loss after dual HER2-directed neoadjuvant therapy for HER2+ breast cancer. Cancer Medicine |
| Crown A, McCartan D, Curry MA, et al. (2023) Pregnancy-associated breast cancer: does timing of presentation affect outcome? Breast Cancer Research and Treatment |
| Page DB, Beal K, Linch SN, et al. (2022) Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases. Npj Breast Cancer. 8: 50 |
| Ferraro E, Singh J, Patil S, et al. (2022) Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. Npj Breast Cancer. 8: 37 |
| Jhaveri K, Drago JZ, Shah PD, et al. (2021) A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with -mutated HER2-positive metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Taylor AM, Chan DLH, Tio M, et al. (2021) PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. The Cochrane Database of Systematic Reviews. 4: CD011395 |
| Copeland-Halperin RS, Al-Sadawi M, Patil S, et al. (2020) Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer. Jama Oncology |
| Ged Y, Gupta R, Duzgol C, et al. (2020) Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. Bmc Urology. 20: 84 |
| Quezada-Diaz FF, Smith JJ, Jimenez-Rodriguez RM, et al. (2020) Patient-Reported Bowel Function in Patients with Rectal Cancer Managed by a Watch-and-Wait Strategy after Neoadjuvant Therapy: A Case-Control Study. Diseases of the Colon and Rectum |
| McHugh DJ, Funt SA, Silber D, et al. (2020) Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902712 |